Evaxion Completes Phase 2 Trial Extension for Personalized Cancer Vaccine EVX-01 — Evaxion A/S

Event summary

Evaxion completed the one-year extension of its Phase 2 trial for EVX-01, a personalized cancer vaccine, with the last patient visit on April 7, 2026.
Three-year clinical efficacy data is expected to be presented in the second half of 2026.
The trial demonstrated a 75% Objective Response Rate in the first two years, with 92% of patients still responding at two years follow-up.
EVX-01 induced an immune response in all patients, with 81% of targeted neoantigens generating potent specific T-cell responses.

The big picture

Evaxion's completion of the Phase 2 trial extension for EVX-01 marks a critical milestone in the development of personalized cancer vaccines. The strong Objective Response Rate and immune response data position EVX-01 as a potential leader in the field, particularly as the industry shifts toward AI-driven drug discovery and precision immunotherapy. The upcoming three-year data will be pivotal in determining the vaccine's long-term viability and commercial potential.

What we're watching

Clinical Efficacy: Whether the three-year data will confirm the durability of EVX-01's immune response and enhanced treatment effects.
Regulatory Pathway: The pace at which Evaxion can advance EVX-01 toward regulatory approval based on the upcoming data.
Market Positioning: How Evaxion's AI-Immunology™ platform will differentiate it in the competitive landscape of cancer vaccines.